Pulse Bio (PLSE) Q3 2026 Earnings Call Transcript

Pulse Biosciences reported 86% of patients in its PRECISE-BTN study achieved at least 50% thyroid nodule volume reduction at six months, with a median reduction of 72%. Quality of life scores improved 78%, and 82% of patients saw resolution of neck pressure or fullness. No serious adverse events were reported. The company plans to release more data as follow-up continues.

PULSE BIOSCIENCES, INC. (PLSE) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Pulse Biosciences Presents Six-Month Interim Results from the PRECISE-BTN Multicenter Study at the American Thyroid Association Annual Meeting 86% of patients evaluated achieved at least 50% nodule volume reduction at six months after a single nonthermal nsPFA treatm

Pulse Biosciences (PLSE) reported interim results from its PRECISE-BTN study, showing 86% of patients achieved at least 50% nodule volume reduction at six months. The median volume reduction was 72%, with no serious adverse events. The company expects to report data for all patients at six and 12 months.

PULSE BIOSCIENCES, INC. (PLSE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pulse Biosciences Reports Business Updates and Third Quarter 2026 Financial Results Completed enrollment of NANOPULSE-AF US IDE pivotal study for treatment of AF with nPulse Cardiac Catheter System Ended the quarter with $189 million of cash, cash equivalents, and ma

Pulse Biosciences (PLSE) completed enrollment for its NANOPULSE-AF study, meeting its target of 164 patients across 15 sites. The study aims to assess the safety and effectiveness of its nPulse Cardiac Catheter System for drug-resistant atrial fibrillation. Analysts forecast revenue of $38.3M and earnings of $4.8M by 2029, with significant growth and earnings swing expected. The trial's outcomes will influence regulatory, reimbursement, and commercialization decisions.

Pulse Biosciences (PLSE) completed enrollment of 164 patients in its NANOPULSE-AF study, three months ahead of schedule. The study evaluates the nPulse Cardiac Catheter System for drug-resistant atrial fibrillation. Primary endpoints will be assessed at 6 and 12 months post-ablation, with updates planned as follow-ups conclude.